Preclinical development of FL-091, a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers

被引：0
|
作者：
Zhang, J. [1 ]
Yang, J. [1 ]
Liu, F. [1 ]
Wong, N. C. L. [1 ]
Thrane, K. T. [2 ]
Hallund, M. W. [2 ]
Gronlund, R. V. [2 ]
机构：
[1] Full Life Technol, Shanghai, Peoples R China
[2] Minerva Imaging ApS, Olstykke, Denmark
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-676
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 46 条
  • [1] Development of 177Lu-FL-091 for the treatment of NTSR1-positive cancers
    Liu, Fa
    Yang, Junyu
    Zhang, Juan
    Wong, Nicholas
    Tang, Zhongmin
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [2] Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/NTSR1 Heterodimers for prostate cancers Imaging
    Wang, Qiong
    Liang, Ying
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [3] Preclinical evaluation of a new technetium-99m labeled neurotensin analogue for NTSR1 targeted radionuclide imaging
    Erfani, Mostafa
    Mikaeili, Azadeh
    Fallah, Zhila
    Goudarzi, Mostafa
    BIOORGANIC CHEMISTRY, 2024, 153
  • [4] A Novel Positive Feedback Loop Between NTSR1 and Wnt/β-Catenin Contributes to Tumor Growth of Glioblastoma
    Xiao, Hualiang
    Zeng, Ying
    Wang, Qiushi
    Wei, Shirong
    Zhu, Xiangfeng
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 43 (05) : 2133 - 2142
  • [5] A novel androgen-independent radiotracer with dual targeting of NTSR1 and PSMA for PET/CT imaging of prostate cancer
    Wang, Qiong
    Li, Zhongjing
    Huang, Yong
    Li, Chengze
    Li, Yiluo
    Peng, Yi
    Sheng, Zonghai
    Liang, Ying
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 282
  • [6] Development of cobalt-55 labelled neurotensin antagonist NOTA-SR142948 for cobalt-58m NTSR1 targeted radionuclide therapy
    Lin, W.
    Cabrera, G. O. Fonseca
    Sarduy, E. Aluicio
    Barnhart, T. E.
    Li, Z.
    Wu, Z.
    Engle, J. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S402 - S403
  • [7] Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment
    Ahmad, Rehan
    Panchamoorthy, Govind
    Raina, Deepak
    Lawney, Brian
    Kharbanda, Surender
    Jasuja, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells
    Chen, Ruoyan
    Rajan, Saravanan
    Overstreet, Michael G.
    Hurt, Elaine M.
    Thomas, Suneetha B.
    Muniz-Medina, Vanessa
    Ward, Christopher
    Sadowska, Agnieszka
    Fleming, Ryan
    Karanth, Subramanya
    Breen, Shannon
    Zheng, Bo
    Wu, Yuling
    Iverson, William O.
    Novick, Steven
    O'Day, Terrence
    Shah, Dipesha P.
    Dimasi, Nazzareno
    Tiberghien, Arnaud C.
    Osbourn, Jane
    Walker, Jill
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (08) : 1649 - 1659
  • [9] Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers
    Zammarchi, Francesca
    Havenith, Karin E. G.
    Chivers, Simon
    Hogg, Paul
    Bertelli, Francois
    Tyrer, Peter
    Janghra, Narinder
    Reinert, Halla W.
    Hartley, John A.
    van Berkel, Patrick H.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 582 - 593
  • [10] Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers
    McDermott, Martina S.
    Gong, Ke Wei
    O'Brien, Neil A.
    Conklin, Dylan
    Hoffstrom, Benjamin
    Lu, Ming
    Zhang, Jun
    Luo, Tong
    Jia, Weiping
    Hong, Jenny J.
    Chau, Kevin
    Davenport, Simon
    Press, Michael F.
    Handly-Santana, Abram
    Brugge, Joan S.
    Drapkin, Ronny
    Glaspy, John A.
    Presta, Leonard
    Slamon, Dennis J.
    CANCER RESEARCH, 2022, 82 (12)
12345